These events underscore Dyadic’s commitment to expanding its global footprint and advancing its mission to revolutionize biomanufacturing with its proprietary C1 and Dapibus™ technology platforms.
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1705993&tp_key=2267a6328b. An archive of the webcast will be available within 24 hours after completion of ...
Dyadic International and Cygnus Technologies formed a strategic partnership for the quantification of host cell proteins (HCPs) from the filamentous fungus Thermothelomyces heterothallica C-1 cells.
Hosted on MSN
DYAI: One Strain To Rule Them All
Dyadic Applied BioSolutions, Inc. (NASDAQ:DYAI) announced second quarter 2025 results and held its first conference call under its new name. As we look ahead to the remainder of 2025, we expect ...
Reflects the Company’s strategic focus on commercializing non-therapeutic proteins and unlocking long-term value from its C1 and Dapibus™ gene expression platforms JUPITER, Fla.--(BUSINESS WIRE)-- ...
CompletedstrategicpivotfromR&Dfocustocommercial focus Rebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial engagement and ...
Dyadic Applied BioSolutions expanded its collaboration with Fermbox Bio, a biotech research & manufacturing company developing and delivering bio-based products through precision fermentation and ...
Dyadic International Inc.'s Dutch subsidiary, Dyadic Nederland BV, has entered into a strategic partnership agreement and collaboration with Rabian BV to develop efficacious, scalable, and affordable ...
Good day, and welcome to the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025. The next presenting company is Dyadic International. [Operator Instructions] I'd now like to turn the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results